Keywords: Imatinib mesylate; Cardiotoxicity; Cardiac progenitor cells; Kit;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Transcriptomic approach; RNA-seq; Daphnia; Imatinib mesylate; Cisplatinum; Etoposide; Anticancer drugs; Genotoxicity;
Keywords: combinatorial drug therapy; imatinib mesylate; dexketoprofen trometamol; nanoparticles; fibrosarcoma; cancer treatment;
Keywords: Sodium alginate; Graft copolymer; N-isopropylacrylamide; Responsive hydrogel; Anti cancer drug; Imatinib mesylate; Controlled drug release;
Keywords: Human serum transferrin; Tyrosine kinase inhibitors; Imatinib mesylate; Fluorescence quenching; Circular dichroism; Zeta potential;
Keywords: Imatinib mesylate; Cytotoxic; Genotoxic; Zebrafish liver cells; HepG2 cells; Human peripheral blood lymphocytes;
Rapid ionic liquid-supported nano-hybrid composite reinforced hollow-fiber electromembrane extraction followed by field-amplified sample injection-capillary electrophoresis: An effective approach for extraction and quantification of Imatinib mesylate in h
Keywords: Electromembrane extraction; Capillary electrophoresis; Imatinib mesylate; Nano-hybrid composite; Sol-gel; Validation;
Keywords: CML; Imatinib mesylate; Second cancers; Side effects;
Keywords: Quillaja saponin; Stearic acid; Solid lipid nanoparticles; Imatinib mesylate; Haemolytic test;
Keywords: 5-Fluorouracil; Etoposide; Imatinib mesylate; Human lymphocytes; Cyto/genotoxicity
Keywords: Chronic myeloid leukemia; Tyrosine kinase inhibitor; Imatinib mesylate; Allogeneic stem cell transplantation;
Keywords: Imatinib mesylate; Polymorphism; Quantification; PXRD; DSC; Stability
Keywords: Cat; Hypereosinophilic syndrome; Eosinophilic dermatitis; Imatinib mesylate; Tyrosine-kinase inhibitorChat; Syndrome hyperéosinophilique; Dermatite éosinophilique; Imatinib mesilate; inhibiteur des tyrosine-kinases
Keywords: Gastrointestinal stromal tumours; Imatinib mesylate; Surgery;
microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells
Keywords: Imatinib resistance; Autophagy; miR-199a-5p; miR-199b-5p; WNT2; Chronic myeloid leukemia (CML); 3-MA; 3-methyladenine; AVO; acidic vesicular organelle; CML; chronic myeloid leukemia; CQ; chloroquine; DMSO; dimethyl sulfoxide; HRP; horseradish peroxidase;
Clinical and Pathological Features of Gastrointestinal Stromal Tumors (GIST) in a Single Institution: A Descriptive Study and Review of the Literature
Keywords: Gastrointestinal stromal tumors; Signs and symptoms; Surgical procedures; Biomarkers tumor; Imatinib mesylate; Prognosis; Tumores del estroma gastrointestinal; Signos y sÃntomas; CirugÃa; Biomarcadores de tumor; Mesilato de imatinib; Pronóstico;
Perfil clÃnico y anatomopatológico de los tumores estromales gastrointestinales de un hospital de área: Estudio descriptivo y revisión de la literatura
Keywords: Tumores del estroma gastrointestinal; Signos y sÃntomas; CirugÃa; Biomarcadores de tumor; Mesilato de imatinib; Pronóstico; Gastrointestinal stromal tumors; Signs and symptoms; Surgical procedures; Biomarkers tumor; Imatinib mesylate; Prognosis;
Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles
Keywords: STAT3; signal transducer and activator of transcription 3; siRNA; small interfering RNA; LbL-AuNP; layer-by-layer assembled gold nanoparticles; IM; imatinib mesylate; SC; stratum corneum; PAMAM; polyamidoamine; SA; sodium alginate; PVP; poly(N-vinyl pyrro
Maximizing the Therapeutic Efficacy of Imatinib Mesylate-Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design
Keywords: imatinib mesylate; nanovesicles; cancer cell lines; in vitro cytotoxicity; optimization;
Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia
Keywords: CML; Chronic Myeloid Leukemia; IM; imatinib mesylate; PB; peripheral blood; CP; chronic phase; AP; accelerated phase; BP; blastic phase; MCR; major cytogenetic response; CCR; complete cytogenetic response; MMR; major molecular response; CMR; complete mole
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Keywords: Bioavailability; Clinical equivalency; Cost savings; Imatinib mesylate; Therapeutic drug monitoring
Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR
Keywords: Imatinib mesylate; KAI1/CD82; Metastasis; Breast cancer; Real-time PCR
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
Keywords: GIST; imatinib mesylate; mutational status; prognostic factors; outcome analysis;
The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinet
Keywords: MIL-101(Cr); Dispersive solid-phase extraction; Imatinib mesylate; Pharmacokinetic; Computational simulation;
Effect of PDGF-Rb antagonist imatinib on endometrial injury repairing in mouse model
Keywords: PDGF-Rb; Endometrium; Imatinib mesylate; BrdU; MVD
Watermelon stomach : insuffisance rénale chronique et/ou Glivec® ?
Keywords: Anémie ferriprive; Coagulation par plasma argon; Ectasies vasculaires; Glivec®; Hémorragie digestive; Insuffisance rénale chronique; Watermelon stomachArgon plasma coagulation; Chronic renal failure; Gastrointestinal bleeding; Imatinib mesylate; Iron defi
STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis
Keywords: c-Abl tyrosine kinase; Imatinib mesylate; Neuronal death; Prion diseases; PrP106-126;
Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease
Keywords: Graft-versus-host disease; Imatinib mesylate; Allogeneic hematopoietic stem cell transplantation; Sclerosis; Fasciitis
Management of Hypereosinophilic Syndromes
Keywords: Idiopathic hypereosinophilic syndrome; FIP1L1-PDGFRA-associated myeloid neoplasm; Lymphocytic variant hypereosinophilic syndrome; Corticosteroid; Imatinib mesylate; Hydroxyurea; Interferon-α; Targeted therapy;
Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways
Keywords: Imatinib mesylate; Chronic myeloid leukemia (CML); ABC transporters; Cyclooxygenase-2 (COX-2); Celecoxib;
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma
Keywords: Cisplatin; Imatinib mesylate; Mesothelioma; PDGFR; Pemetrexed
Safranal, a Crocus sativus L constituent suppresses the growth of K-562 cells of chronic myelogenous leukemia. In silico and in vitro study
Keywords: CML; chronic myelogenous leukemia; SFR; safranal; CRC; crocin; IM; imatinib mesylate; Cytotoxicity; XTT assay; K-562 cells; In silico molecular docking; Bcr-Abl gene expression;
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome
Keywords: Chronic myeloid leukemia; Imatinib mesylate; BCR-ABL dependent mechanisms; Tyrosine kinase domain; Mutation;
Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP)
Keywords: CML-CP; Imatinib mesylate; Major molecular response; RQ-PCR
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients
Keywords: ABCB1; ABCG2; Chronic myeloid leukemia; Imatinib mesylate; Single nucleotide polymorphisms
Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: Prognostic implications
Keywords: GIST; Gastrointestinal stromal tumour; Coexistence; Malignancy; Imatinib mesylate
Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib-a single institution historical experience
Keywords: Chronic myeloid leukemia; BCR-ABL transcript; Interferon-α; Imatinib mesylate; Prognostic value;
Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition
Keywords: Wnt5a; Chronic myeloid leukaemia; Imatinib Mesylate; JNK; β-Catenin; γ-Catenin;
Study of polymorphism in imatinib mesylate: A quantum chemical approach using electronic and vibrational spectra
Keywords: Imatinib mesylate; Polymorphism; Raman; Infrared; UV–vis spectroscopy; Quantum mechanical calculations
Imatinib-associated hyperpigmentation of the palate in post-HSCT patient
Keywords: Imatinib mesylate; Hematopoietic stem cell transplant; Oral pigmentation
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib
Keywords: Imatinib mesylate; Chronic myeloid leukemia; ABCB1; Polymorphism
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Keywords: Chronic myeloid leukemia; Complete molecular response; Imatinib mesylate; Real-time quantitative polymerase chain reaction
Determination of imatinib mesylate and related compounds by field amplified sample stacking with large volume sample injection capillary electrophoresis
Keywords: Imatinib mesylate; Capillary electrophoresis; Large volume sample injection; Field amplified sample stacking; Drug quality control;
Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients
Keywords: GIST; IGF; Imatinib mesylate; Metastatic; Prediction; Response
Treatment of polycythemia vera with imatinib mesylate
Keywords: Imatinib mesylate; Polycythemia vera; Myeloproliferative disorder; Myeloproliferative neoplasm; Tyrosine kinase inhibitor; Myelosuppresive therapy;
Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms
Keywords: UPLC; Imatinib Mesylate; Validation; Stability-indicating; Related substance
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
Keywords: Positron emission tomography; Fluorodeoxyglucose; Imatinib mesylate; c-kit; Receptor protein-tyrosine kinase; Gastrointestinal stromal tumour; Soft-tissue sarcoma
The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate
Keywords: Chromosomal abnormality; chronic myeloid leukemia; imatinib mesylate
Efficacité et rémission durables après traitement par imatinib mésylate pour une cardiomyopathie éosinophilique à transcrit FIP1L1-PDGFRA négatif
Keywords: Hyperéosinophilie; Syndrome hyperéosinophilique; Cardiomyopathie; Transcrit FIP1L1-PDGFRA; Imatinib mésylate; Eosinophilia; Hypereosinophilic syndrome; Cardiomyopathy; FIP1L1-PDGFRA transcript; Imatinib mesylate;
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcom
Keywords: Gastrointestinal stroma tumours; Sarcoma; Imatinib mesylate